-
Imperial College Scientists Dose First Patient With 5-MeO-DMT To Examine One Of The Most Potent Psychedelics' Effects On The Brain
Monday, June 3, 2024 - 7:00am | 566Read More...Private psychedelics medicine company Beckley Psytech confirmed Monday that the first patient has been dosed in a new research study investigating the neurophysiological effects of BPL-003, the company's novel synthetic intranasal formulation of 5-MeO-DMT (also known as mebufotenin), on the human...
-
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
Friday, April 26, 2024 - 9:10am | 495Read More...Private psychedelics medicine company Beckley Psytech Ltd announced this week that the first patient has been dosed in the second part of its two-part Phase IIa study evaluating BPL-003 in patients with treatment-resistant depression (TRD). BPL-003 is its proprietary...
-
Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development
Thursday, January 4, 2024 - 3:17pm | 748Read More...Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions. Following the investment -$40 million direct and an...
-
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
Thursday, May 4, 2023 - 4:37pm | 341Read More...Clinical-stage private biotech company Beckley Psytech Ltd announced that the first patient has been dosed in their Phase IIa study of BPL-003, a synthetic formulation of the psychedelic compound 5-MeO-DMT, for Treatment-Resistant Depression (TRD). Dr. Rob Conley, chief scientific officer at...
